OTC: RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.CIK 0001742927 · SIC 2834 · Pharmaceutical Preparations
Common stock, par value of $0.0001; 515,000,000 and 315,000,000 shares authorized; 5,872,865 and 2,359,327 shares issued and outstanding as of December 31, 2025 and 2024, respectively About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (CNXC 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade RVPH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Nov 13, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended September 30, 2026 | Three months ended September 30, 2025 | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | 1,198,460 | 2,131,444 | 4,028,164 | 9,969,736 |
| General and administrative | 1,234,058 | 1,898,397 | 4,293,849 | 6,671,254 |
| Total operating expenses | 2,432,518 | 4,029,841 | 8,322,013 | 16,640,990 |
| Loss from operations | (2,432,518) | (4,029,841) | (8,322,013) | (16,640,990) |
| Other income (expense) | ||||
| (Loss) gain on remeasurement of warrant liabilities | — | (27,816) | — | 44,504 |
| Interest expense | (1,174) | (2,605) | (10,762) | (19,022) |
| Interest income | 135,329 | 59,103 | 401,002 | 168,061 |
| Other income (expense), net | 1,392 | (6,774) | (3,038) | (33,769) |
| Total other income, net | 135,547 | 21,908 | 387,202 | 159,774 |
| Loss before provision for income taxes | (2,296,971) | (4,007,933) | (7,934,811) | (16,481,216) |
| Provision for income taxes | 1,934 | 2,840 | 7,912 | 16,007 |
| Net loss | (2,298,905) | (4,010,773) | (7,942,723) | (16,497,223) |
| Net loss per share: | ||||
| Basic and diluted | (0.17) | (1.09) | (0.71) | (5.71) |
| Weighted average shares outstanding | ||||
| Basic and diluted | 13,208,816 | 3,664,647 | 11,169,518 | 2,887,726 |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | September 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | 17,458,418 | 14,438,792 |
| Prepaid clinical trial costs | 819,721 | — |
| Prepaid expenses and other current assets | 279,186 | 664,685 |
| Total current assets | 18,557,325 | 15,103,477 |
| Non-current prepaid clinical trial costs | — | 819,721 |
| Total Assets | 18,557,325 | 15,923,198 |
| Liabilities and Stockholders’ Equity | ||
| Liabilities | ||
| Short-term debt | 44,388 | 406,875 |
| Accounts payable | 2,476,554 | 3,009,074 |
| Accrued clinical expenses | 2,103,213 | 2,582,094 |
| Accrued compensation | 654,575 | 485,899 |
| Other accrued liabilities | 199,234 | 791,611 |
| Total current liabilities | 5,477,964 | 7,275,553 |
| Total Liabilities | 5,477,964 | 7,275,553 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ Equity | ||
| Common stock, par value of $0.0001; 515,000,000 shares authorized; 13,110,377 and 5,872,865 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 12,378 | 11,655 |
| Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 205,147,658 | 192,773,942 |
| Accumulated deficit | (192,080,675) | (184,137,952) |
| Total stockholders' equity | 13,079,361 | 8,647,645 |
| Total Liabilities and Stockholders’ Equity | 18,557,325 | 15,923,198 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (7,942,723) | (16,497,223) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Change in fair value of warrant liabilities | — | (44,504) |
| Stock-based compensation expense | 970,025 | 1,772,775 |
| Changes in operating assets and liabilities: | ||
| Prepaid clinical trial costs (current and non-current) | — | 458,859 |
| Prepaid expenses and other current assets | 306,749 | 418,508 |
| Accounts payable | (532,520) | (1,210,527) |
| Accrued expenses and other current liabilities | (902,582) | (3,694,320) |
| Net cash used in operating activities | (8,101,051) | (18,796,432) |
| Cash flows from financing activities | ||
| Repayment of short-term debt | (362,487) | (458,154) |
| Proceeds from issuance of common stock in ATM offering, net of transaction costs paid | 2,528,936 | 1,300,686 |
| Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants in offerings, net of transaction costs paid | 8,954,190 | 17,419,703 |
| Proceeds from exercise of common stock warrants | 38 | 241,125 |
| Net cash provided by financing activities | 11,120,677 | 18,503,360 |
| Net increase (decrease) in cash and cash equivalents | 3,019,626 | (293,072) |
| Cash and cash equivalents, beginning of period | 14,438,792 | 13,476,331 |
| Cash and cash equivalents, end of period | 17,458,418 | 13,183,259 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for taxes | 675 | 3,369 |
| Cash paid for interest | 10,762 | 19,022 |
| Noncash Investing and Financing Activities: | ||
| Issuance of common stock warrants | 5,149,950 | 9,766,116 |
| Issuance of pre-funded warrants | 214,198 | — |
| Transaction costs related to offerings included in accounts payable and accrued expenses | — | 499,903 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
About REVIVA PHARMACEUTICALS HOLDINGS, INC.
Source: Item 1 (Business) from the 10-K filed March 30, 2026. Description as filed by the company with the SEC.
Item 1. Financial Statements
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
December 31,
December 31,
2025
2024
Assets
Cash and cash equivalents
$
14,438,792
$
13,476,331
Prepaid clinical trial costs
—
540,601
Prepaid expenses and other current assets
664,685
666,435
Total current assets
15,103,477
14,683,367
Non-current prepaid clinical trial costs
819,721
819,721
Total Assets
$
15,923,198
$
15,503,088
Liabilities and Stockholders’ Equity
Liabilities
Short-term debt
$
406,875
$
458,154
Accounts payable
3,009,074
6,283,430
Accrued clinical expenses
2,582,094
6,723,719
Accrued compensation
485,899
635,587
Other accrued liabilities
791,611
500,616
Total current liabilities
7,275,553
14,601,506
Warrant liabilities
—
89,010
Total Liabilities
7,275,553
14,690,516
Commitments and contingencies (Note 6)
Stockholders’ Equity
Common stock, par value of $0.0001; 515,000,000 and 315,000,000 shares authorized; 5,872,865 and 2,359,327 shares issued and outstanding as of December 31, 2025 and 2024, respectively
11,655
4,658
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024
—
—
Additional paid-in capital
192,773,942
165,080,964
Accumulated deficit
(184,137,952
)
(164,273,050
)
Total stockholders' equity
8,647,645
812,572
Total Liabilities and Stockholders’ Equity
Read full description ↓
$
15,923,198
$
15,503,088
The accompanying notes are an integral part of these consolidated financial statements.
F-3
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended December 31,
2025
2024
Operating expenses
Research and development
$
11,708,906
$
22,907,368
General and administrative
8,491,125
7,891,521
Total operating expenses
20,200,031
30,798,889
Loss from operations
(20,200,031
)
(30,798,889
)
Other income (expense)
Gain on remeasurement of warrant liabilities
89,010
717,645
Interest expense
(13,402
)
(18,497
)
Interest income
311,370
361,369
Other expense, net
(32,960
)
(160,916
)
Total other income, net
354,018
899,601
Loss before provision for income taxes
(19,846,013
)
(29,899,288
)
Provision for income taxes
18,889
19,514
Net loss
$
(19,864,902
)
$
(29,918,802
)
Net loss per share:
Basic and diluted
$
(5.48
)
$
(17.73
)
Weighted average shares outstanding
Basic and diluted
3,627,890
1,687,738
The accompanying notes are an integral part of these consolidated financial statements.
F-4
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
Additional
Total
Common Stock
Paid-In
Accumulated
Stockholders'
Shares
Amount
Capital
Deficit
Equity
Balance at December 31, 2024
2,359,327
$
4,658
$
165,080,964
$
(164,273,050
)
$
812,572
Common stock issued in connection with warrant exercises
997,738
1,995
6,974,070
—
6,976,065
Issuance of common stock in At-The-Market (ATM) offering, net of transaction costs
150,800
302
1,466,838
—
1,467,140
Issuance of common stock in June 2025 and September 2025 public offerings, net of transaction costs
2,350,000
4,700
7,258,095
—
7,262,795
Issuance of common stock warrants in June 2025 and September 2025 public offerings, net of transaction costs
—
—
9,766,116
—
9,766,116
Vesting of restricted common stock issued to consultant for services
15,000
—
—
—
—
Stock-based compensation expense
—
—
2,227,859
—
2,227,859
Net loss
—
—
—
(19,864,902
)
(19,864,902
)
Balance at December 31, 2025
5,872,865
$
11,655
$
192,773,942
$
(184,137,952
)
$
8,647,645
F-5
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
Additional
Total
Common Stock
Paid-In
Accumulated
Stockholders'
Shares
Amount
Capital
Deficit
Equity
Balance at December 31, 2023
1,426,294
$
2,792
$
140,070,172
$
(134,354,248
)
$
5,718,716
Common stock issued in connection with prefunded warrant exercises
74,283
149
—
—
149
Issuance of common stock in offering, net of transaction costs
858,750
1,717
10,918,984
—
10,920,701
Issuance of common stock warrants in offering, net of transaction costs
—
—
10,421,225
—
10,421,225
Issuance of prefunded warrants in offering, net of transaction costs
—
—
470,057
—
470,057
Issuance of underwriter warrants in offering
—
—
165,952
165,952
Modification of existing warrants, net of transaction costs
—
—
1,073,416
—
1,073,416
Stock-based compensation expense
—
—
1,630,341
—
1,630,341
Settlement of bonuses in form of stock options
—
—
330,816
—
330,816
Net loss
—
—
—
(29,918,802
)
(29,918,802
)
Balance at December 31, 2024
2,359,327
$
4,658
$
165,080,964
$
(164,273,050
)
$
812,572
The accompanying notes are an integral part of these consolidated financial statements.
F-6
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
2025
2024
Cash flows from operating activities
Net loss
$
(19,864,902
)
$
(29,918,802
)
Adjustments to reconcile net loss to net cash used in operating activities
Change in fair value of warrant liabilities
(89,010
)
(717,645
)
Stock-based compensation expense
2,227,859
1,630,341
Changes in operating assets and liabilities:
Prepaid clinical trial costs (current and non-current)
540,601
(1,282,027
)
Prepaid expenses and other current assets
1,750
(411,798
)
Accounts payable
(3,407,773
)
2,291,186
Accrued expenses and other current liabilities
(4,003,168
)
(5,135,171
)
Net cash used in operating activities
(24,594,643
)
(33,543,916
)
Cash flows from financing activities
Proceeds from issuance of short-term debt
406,875
976,904
Repayment of short-term debt
(458,154
)
(518,750
)
Proceeds from issuance of common stock in ATM offering, net of transaction costs paid
1,477,407
—
Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs paid
17,154,911
23,194,488
Proceeds from exercise of common stock warrants
6,976,065
149
Net cash provided by financing activities
25,557,104
23,652,791
Net increase (decrease) in cash and cash equivalents
962,461
(9,891,125
)
Cash and cash equivalents, beginning of period
13,476,331
23,367,456
Cash and cash equivalents, end of period
$
14,438,792
$
13,476,331
Supplemental disclosures of cash flow information:
Cash paid for taxes
$
3,369
$
3,417
Cash paid for interest
$
13,402
$
18,497
Noncash Investing and Financing Activities:
Settlement of bonuses in form of stock options
$
—
$
330,816
Warrant modification recorded in stockholders' equity
$
—
$
1,073,416
Issuance of common stock warrants
$
9,766,116
$
10,421,225
Issuance of prefunded warrants
$
—
$
470,057
Issuance of underwriter warrants
$
—
$
165,952
Transaction costs related to offerings included in accounts payable and accrued expenses
$
136,267
$
143,136
The accompanying notes are an integral part of these consolidated financial statements.
F-7
REVIVA PHARMACEUTICALS HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2025 and 2024
1. ORGANIZATION AND NATURE OF OPERATIONS
Reviva Pharmaceuticals Holdings, Inc. (together with its consolidated subsidiaries, the “Company”) is a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system ("CNS"), inflammatory and cardiometabolic diseases.
Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in 2014. In these notes to the consolidated financial statements, unless otherwise specified or the context indicates otherwise, references to the “Company,” “Reviva,” “we,” “us” and “our” refer to Reviva Pharmaceuticals Holdings, Inc. and its consolidated subsidiaries.
Reverse Stock Split
On March 9, 2026, Reviva completed a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The Reverse Split did not change the number of authorized shares of common stock or par value of common stock. No cash or fractional shares were issued in connection with the Reverse Split, and instead the Company rounded up to the next whole share in lieu of issuing factional shares that would have been issued in the Reverse Split. Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company’s outstanding stock options, restricted common stock, and warrants, the exercise price of the Company’s outstanding stock options, restricted common stock and warrants, and the number of shares reserved for issuance under the Company’s equity incentive plan. All share, common stock warrant, prefunded warrant, restricted common stock and common stock option amounts, and per share, per common stock warrant, per prefunded warrant, per restricted common stock and per common stock option amounts, in these consolidated financial statements have been retrospectively adjusted as appropriate to reflect the Reverse Stock Split.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
Basis of presentation
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity.
Principles of consolidation
The accompanying consolidated financial statements include the accounts of Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiaries Reviva Pharmaceuticals, Inc. and Reviva Pharmaceuticals India Pvt. Ltd. The Company's foreign subsidiary’s functional currency is the U.S. dollar. The Company recognizes a foreign currency transaction gain or loss each reporting period as part of other expense, net, on the consolidated statement of operations. The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. All transactions and balances between the parent and its subsidiaries have been eliminated in consolidation.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and assess performance. The Company and the Company’s CODM, the Company’s chief executive officer, view the Company’s operations and manage its business as a single operating segment. See Note 9, Segment Information, for more information.
F-8
Liquidity and going concern
The Company has incurred losses since inception and as of December 31, 2025, the Company had a working capital surplus of approximately $7.8 million, an accumulated deficit of $184.1 million and cash and cash equivalents on hand of approximately $14.4 million. The Company's net loss for the years ended December 31, 2025 and 2024, was approximately $19.9 million and $29.9 million, respectively. The Company expects to incur significant expenses and increased operating losses for the next several years. The Company expects its expenses to increase in connection with its ongoing activities to research, develop and commercialize its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so.
The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the date that the consolidated financial statements are issued. The Company believes that it has adequate cash on hand to cover anticipated outlays into early 2027 but will need additional fundraising activities and cash on hand prior to such time. The Company has based this estimate, however, on assumptions that may prove to be wrong, and could spend available financial resources much faster than it currently expects. The Company will need to raise additional funds to continue funding its development efforts and operations. The Company intends to secure such additional funding, although there are no guarantees or commitments for additional funding. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. The amount and timing of the Company's future funding requirements will depend on many factors, including the pace and results of the Company's clinical development efforts. The Company will seek to fund its operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. During 2025, the Company raised capital through registered financial offerings, including public offerings of common stock and warrants and sales of common stock pursuant to the Company's May 2025 ATM Sales Agreement (Note 4). Refer to Note 10, Subsequent Events, for information about financing activity after December 31, 2025, including additional sales of common stock under the May 2025 ATM Sales Agreement and the Company's March 2026 Public Offering. Adequate additional financing may not be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying, discontinuing certain clinical activities or ceasing operations. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
Use of estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods covered by the consolidated financial statements and accompanying notes. Significant items subject to such estimates and assumptions include clinical trial costs, fair value of stock-based compensation, and fair value of warrants. Actual results could differ materially from such estimates under different assumptions or circumstances.
Concentration of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all the Company’s cash and cash equivalents are held in demand deposit and money market funds at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. Amounts held in demand deposit in excess of federally insured limits, totaled $878,844 and $937,004 as of December 31, 2025 and December 31, 2024, respectively. To date, the Company has not experienced any losses on its deposits of cash.
The Company is subject to all of the risks inherent in a clinical-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry.
The Company contracts with vendors and consultants to provide services related to the Company’s research and development. Costs and expenses incurred that represented 10% or more of research and development costs for the years ended December 31, 2025 and 2024 consisted of the following: during the year ended December 31, 2025 costs from one vendor represented 39% of total research and development expenses and during the year ended December 31, 2024 costs from two vendors represented 40% and 14% of total research and development expenses, respectively.
F-9
The Company’s operating results may be materially affected by the foregoing factors.
Cash and cash equivalents
As of December 31, 2025 and 2024 the Company’s cash was maintained in demand deposit forms at three financial institutions. The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents.
The components of cash and cash equivalents were as follows:
As of December 31, 2025
As of December 31, 2024
Cash on deposit
$
1,210,072
$
1,272,704
Money market funds (cash equivalents)
13,228,720
12,203,627
Cash and cash equivalents
$
14,438,792
$
13,476,331
Leases
The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (“ROU”) assets and the corresponding lease liabilities are included in lease liability, current and lease liability, on the Company’s balance sheets. ROU assets represent the Company's right to use an underlying asset, and lease liabilities represent the Company's obligation to make lease payments in exchange for the ability to use the asset for the duration of the lease term. The option to extend a lease is included in the lease term only when it is reasonably certain that the Company will elect that option. Additionally, the Company does not record ROU assets or lease liabilities for short-term leases that have a term of twelve months or less at lease commencement.
ROU assets and lease liabilities are recognized at the commencement date and determined using the present value of the future minimum lease payments over the lease term. For any identified leases not determined to be short-term, The Company uses an incremental borrowing rate based on an estimated rate of interest for collateralized borrowing for any leases that do not include an implicit interest rate. Where applicable, the estimated incremental borrowing rate considers market data, actual lease economic environment, and the lease term at commencement date.
Fair value measurements
Accounting Standards Codification ("ASC") 820, Fair Value Measurements ("ASC 820"), defines fair value, establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy under ASC 820 are described below:
•
Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
•
Level 2 - Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
F-10
•
Level 3 - Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
The Company's equity classified and liability classified warrants measured at fair value using significant unobservable inputs and are therefore categorized within Level 3 of the fair value hierarchy. In determining the fair value of equity classified warrants, the Company utilizes the Black-Scholes-Merton model using assumptions regarding volatility, expected term of the warrants, expected divided rate, and risk-free interest rates. In determining the fair value of liability classified warrants, the Company utilizes a Lattice model using assumptions regarding volatility, expected term of the warrants, expected dividend, and risk-free interest rates. These assumptions are described as:
•
Expected term: The Company’s expected term represents the period between the valuation date and the expiration date of the warrant; however, if an estimated liquidation event is expected to occur and the warrants are affected by said liquidation event, the period between the valuation date and that event would be used instead.
•
Expected volatility: Expected volatility for equity classified awards is based on historical stock volatility data for a peer set of similar public companies with sufficient trading history, over the expected term of the warrant, or Company stock volatility when sufficient trading history exists. Expected volatility for liability classified warrants is based on the volatility implied by the public warrant market price when sufficient data is available; otherwise it is based on a peer set of similar public companies.
•
Expected dividend: The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.
•
Risk-free interest rate: The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury zero-coupon issues in effect at the valuation date for periods corresponding with the expected term of the warrant.
Due to their short maturities, the carrying amounts for cash and cash equivalents, prepaid clinical trial costs, prepaid expenses and other current assets, accounts payable, accrued clinical expenses, accrued compensation, short-term debt, and other accrued liabilities approximate their fair value.
Clinical trial costs
The Company records clinical trial costs as they are incurred. For any unbilled costs as of each reporting date, the Company determines the amounts to accrue by obtaining reports from its vendors, including the Company's contract research organizations (“CROs”), and communicating with the Company's personnel and suppliers to identify services that have been performed, but not yet billed. The Company further validates the completeness of its accruals by reconciling payments and invoices, and reviewing vendor contracts and purchase orders. As necessary, the Company obtains milestones and percentage completion reports from vendors and will estimate the level of service performed and the associated cost incurred for the services when the Company have not yet been invoiced or otherwise notified of the actual cost.
During the year-ended December 31, 2025 all patient visits concluded and clinical sites were closed. Clinical trial costs were therefore recorded based on actual costs to date provided by the Company's CROs, as the clinical trials in progress are in the wind-down phase. Previously, the Company's accrued clinical trial costs for patients and sites included the calculation of patient visits incurred, but not yet reported by the vendor. The calculation previously involved the use of key inputs and assumptions such as estimated budget, estimated unreported costs based on historical trending of reported costs to date, and projected costs remaining until the conclusion of the trials which is no longer necessary given the status of the clinical trials.
For all other clinical trial costs the Company's estimated accrued expenses are based on facts and circumstances known to the Company at that time. The Company will confirm the accuracy of its estimates with the service providers and adjust if necessary.
F-11
Research and development costs
Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not limited to, costs associated with the Company’s clinical trials, payroll and personnel expenses, stock-based compensation charges for those individuals involved in ongoing research and development efforts, laboratory supplies and consulting costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.
The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on the Company’s behalf.
General and administrative costs
General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not limited to, payroll and personnel expenses, travel and entertainment, consulting costs, professional services, conference and meeting costs, legal expenses and overhead, including rent and utilities.
Income taxes
The Company utilizes ASC 740, Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.
The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.
In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss ("NOL") carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.
Stock-based compensation
Stock-based compensation is calculated based on the requirements of ASC 718, Share-Based Payments ("ASC 718"), which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The fair value of the award is recognized as expense based upon the vesting terms of the award over the requisite service period. The Company accounts for forfeited awards as they occur.
F-12
In determining the fair value of awards, the Company utilizes the Black-Scholes-Merton model using assumptions regarding volatility of the Company's common share price, expected term, expected divided rate, and risk-free interest rates as described below:
•
Expected term: The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method.
•
Expected volatility: Expected volatility is based on historical stock volatility data for a peer set of similar public companies with sufficient trading history, over the expected term of the awards.
•
Expected dividend: The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.
•
Risk-free interest rate: The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.
Short-term debt
In December 2025 and 2024, the Company obtained new financing for the renewal of certain policy premiums related to Director and Officers liability insurance. The governing agreement assigns the lender a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies.
The total premiums, taxes, and fees financed during 2025 was $406,875, of which a principal balance of $325,500 was financed after accounting for the up-front payment made. The total premiums, taxes, and fees financed during 2024 was $458,154, of which a principal balance of $366,523 was financed after accounting for the up-front payment made. The 2025 financing arrangement provided for an annual percentage interest rate of 7.15% and a term of 10 months, with ten payments, inclusive of interest, payable on a monthly basis beginning January 2026 and continuing through October 2026. The 2024 financing arrangement provided for an annual percentage interest rate of 7.90% and a term of 10 months, with ten payments, inclusive of interest, payable on a monthly basis beginning January 2025 and continuing through October 2025.
New accounting pronouncements adopted
In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to require entities to disclose specific categories in the rate reconciliation, the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and income tax expense or benefit from continuing operations (separated by federal, state and foreign). The Company adopted ASU 2023-09 and applied the disclosure requirements on a prospective basis effective for the year ended December 31, 2025 (Note 8). The adoption did not affect our financial position or our results of operations, but resulted in additional disclosures.
New accounting pronouncements not yet adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to require disclosure, in the notes to the consolidated financial statements, of specified information about certain costs and expenses. This ASU was further clarified by ASU 2025-01, Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures, Disaggregation of Income Statement Expenses, which was issued in December 2024. The effective date for the standard is for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.
F-13
3. NET LOSS PER SHARE
Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common shares and pre-funded warrants outstanding during the period. Diluted net loss per share includes potentially dilutive securities such as stock options, and warrants to purchase common stock (excluding prefunded warrants that are exercisable for $0.002 per warrant) unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2025 and 2024, because all such securities are anti-dilutive for all periods presented.
The components of basic and diluted net loss per share were as follows:
Year Ended December 31,
2025
2024
Numerator:
Net loss
$
(19,864,902
)
$
(29,918,802
)
Denominator:
Weighted-average common shares outstanding – basic and diluted
3,627,890
1,687,738
Net loss per share – basic and diluted
$
(5.48
)
$
(17.73
)
The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive:
Year Ended December 31,
2025
2024
Shares issuable upon exercise of stock options
158,098
127,972
Shares issuable upon exercise of warrants to purchase common stock (excluding 98,439 prefunded warrants that are exercisable for $0.002 per warrant as of December 31, 2025 and 2024, respectively)
5,344,068
2,289,130
5,502,166
2,417,102
The diluted net loss per share computation equals basic net loss per share for the years ended December 31, 2025 and 2024 because the Company had a net loss and the impact of the assumed exercise of stock options and certain warrants would be anti-dilutive.
F-14
4. WARRANTS
The following is a summary of the Company’s warrant activity (number of common stock shares underlying the warrants) for the year ended December 31, 2025:
Warrant Issuance
Issuance Date
Exercise Price
Outstanding,
December 31, 2024
Warrant Shares Issued
Warrant Shares Exercised
Warrant Shares Cancelled/ Expired
Outstanding, December 31 2025
Expiration Date
SPAC Public Warrants
December 2020
$
230.00
344,066
—
—
(344,066
)
—
December 2025
June 2021 Common Stock Warrants
June 2021
$
82.500
222,254
—
—
—
222,254
May 2026
June 2021 Common Stock Warrants (August 2024 Amended)*
June 2021
$
15.9280
109,999
—
—
—
109,999
August 2029
Pre-Public Private Company Warrants
December 2020
$
459.80
6,023
—
—
(6,023
)
—
July 2025
September 2022 Private Pre-Funded Warrants
September 2022
$
0.002
69,170
—
—
—
69,170
September 2027
September 2022 Common Stock Warrants
September 2022
$
48.00
69,170
—
—
—
69,170
September 2027
November 2023 Common Stock Warrants
November 2023
$
100.00
97,560
—
—
—
97,560
November, 2028
November 2023 Common Stock Warrants (May 2024 Amended)**
November 2023
$
29.100
68,293
—
—
—
68,293
May 2029
November 2023 Common Stock Warrants (August 2024 Amended)***
November 2023
$
15.9280
126,830
—
—
—
126,830
August 2029
November 2023 Pre-Funded Warrants
November 2023
$
0.002
29,269
—
—
—
29,269
November 2028
May 2024 Common Stock Warrants
May 2024
$
29.100
94,937
—
—
—
94,937
May 2029
August 2024 Common Stock Warrants
August 2024
$
15.9280
238,096
—
—
—
238,096
August 2029
August 2024 Underwriter Warrants
August 2024
$
26.2500
11,905
—
—
—
11,905
August 2029
December 2024 Series A Common Stock Warrants
December 2024
$
30.00
300,000
—
(2,763
)
(297,237
)
—
June 2025
December 2024 Series B Common Stock Warrants
December 2024
$
30.00
600,000
—
(5,275
)
—
594,725
December 2029
June 2025 Series C Common Stock Warrants
June 2025
$
10.00
—
1,000,000
(7,175
)
—
992,825
June 2030
June 2025 Series D Common Stock Warrants
June 2025
$
10.00
—
1,000,000
(24,325
)
—
975,675
June 2026
September 2025 Series E Common Stock Warrants
September 2025
$
6.700
—
1,350,000
(132,150
)
—
1,217,850
September 2030
September 2025 Series F Common Stock Warrants
September 2025
$
6.700
—
1,350,000
(826,050
)
—
523,950
September 2026
2,387,572
4,700,000
(997,738
)
(647,326
)
5,442,508
* In August 2024, 109,999 of these warrants were modified to reduce the exercise price from $82.50 per warrant share, to $15.93 per warrant share and to extend the expiration of these warrants from May 2026 to August 2029.
** In May 2024, 68,293 of these warrants were modified to reduce the exercise price from $100 per warrant share, to $29.10 per warrant share and to extend the expiration of these warrants from November 2028 to May 2029.
*** In August 2024, 126,830 of these warrants (separate from the May 2024 modification) were modified to reduce the exercise price from $100 per warrant share, to $15.93 per warrant share and to extend the expiration of these warrants from November 2028 to August 2029.
F-15
May 2024 Registered Direct Offering
On May 29, 2024, the Company completed a registered direct offering (the “May 2024 Offering”), priced at the market under Nasdaq rules, and the Company sold and issued an aggregate of (i) 94,937 shares of its common stock, and (ii) warrants (the “May 2024 Common Stock Warrants”) exercisable for an aggregate of up to 94,937 shares of its common stock. The public offering price for each share of common stock and accompanying May 2024 Warrants to purchase one share of common stock was $31.60. The May 2024 Common Stock Warrants have a term of 5 years and expire on May 29, 2029. The net proceeds to the Company from the May 2024 Offering were $2.8 million, after deducting placement offering costs, agent fees and expenses and other offering expenses payable by the Company, of $0.4 million.
The Company evaluated the May 2024 Common Stock Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The May 2024 Common Stock Warrants are indexed to the Company’s common stock and are required to be settled through physical settlement, subject to certain conditions, or net share settlement, if exercised. Accordingly, the May 2024 Common Stock Warrants were recorded at their grant date fair value with no subsequent remeasurement.
The fair value of the May 2024 Common Stock Warrants was determined utilizing a Black-Scholes-Merton model, considering all relevant assumptions current at the date of issuance. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for further detail regarding how assumptions were determined. The grant date relative fair value of the May 2024 Common Stock Warrants was estimated to be approximately $1.1 million recognized to additional paid-in capital in the consolidated balance sheet as the May 2024 Common Stock Warrants were determined to be equity classified, with the corresponding debit as an issuance cost of the related equity offering.
The following assumptions and key inputs were used to value the May 2024 Common Stock Warrants at the date of issuance:
Risk-free interest rate
4.6
%
Expected term (years)
5
Expected volatility
93.00
%
Stock price on valuation date
$
26.80
Exercise price
$
29.20
Expected dividend
—
%
F-16
Accounting for Warrant Modification
In connection with the May 2024 Offering, on May 28, 2024, the Company entered into a warrant amendment agreement with the purchaser party to the Purchase Agreement, pursuant to which the Company agreed to amend the purchaser’s existing warrants to purchase 68,293 shares of common stock at an exercise price of $100 per share issued in November 2023 (the “May 2024 Existing Warrants”) in consideration for such purchaser party’s participation and purchase of approximately $3.0 million of securities in the May 2024 Offering and the payment of $0.2 million to (i) lower the exercise price of the May 2024 Existing Warrants to $29.10 per share and (ii) amend the expiration date of the May 2024 Existing Warrants to five years following the closing of the May 2024 Offering, effective upon the closing of the May 2024 Offering on May 29, 2024.
ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging ("ASC 815") require issuers to account for modifications or exchanges of freestanding equity-classified written call options (e.g., warrants) that remain equity classified after the modification or exchange based on the economic substance of the modification or exchange. Pursuant to ASC 480 and ASC 815, the Company accounts for modifications of equity-classified warrant agreements by recording any increase in fair value of the modified equity-classified warrant as an equity issuance cost that reduces additional paid-in capital. The increase in the fair value of the modified May 2024 Existing Warrants was determined to be $0.2 million.
The following assumptions and key inputs were used to value the modification of the May 2024 Existing Warrants immediately before the modification and immediately after the modification:
Immediately before the modification
Immediately after the modification
Risk-free interest rate
4.70
%
4.60
%
Expected term (years)
4.5
5.0
Expected volatility
97.00
%
93.00
%
Stock price on valuation date
$
26.80
$
26.80
Exercise price
$
100.00
$
29.20
Expected dividend
—
%
—
%
August 2024 Underwritten Offering
On August 22, 2024, the Company completed an underwritten offering and the Company sold and issued (i) 163,813 shares of common stock, (ii) pre-funded warrants (the “August 2024 Pre-Funded Warrants”) exercisable for an aggregate of up to 74,282 shares of common stock, and (iii) warrants (the “August 2024 Common Stock Warrants”) exercisable for an aggregate of 238,095 shares of common stock (the “August 2024 Offering”). The public offering price for each share of common stock and accompanying August 2024 Common Stock Warrants to purchase one share of common stock (including the pricing for the warrant repricing described below) was $21, and the public offering price for each August 2024 Pre-Funded Warrants and accompanying August 2024 Common Stock Warrants to purchase one share of common stock was $20.998. The net proceeds to the Company from the August 2024 Offering were approximately $3.6 million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company of approximately $1.4 million.
F-17
Upon the closing of the August 2024 Offering, the Company issued to the Underwriter warrants to purchase up to 11,905 shares of common stock (the “August 2024 Underwriter Warrants”). The August 2024 Underwriter Warrants are exercisable at an exercise price of $26.25 per share and are exercisable during the five-year period commencing six months after the closing date of the August 2024 Offering.
The Company evaluated the August 2024 Common Stock Warrants and August 2024 Pre-funded Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The August 2024 Common Stock Warrants are indexed to the common stock and are required to be settled through physical settlement, subject to certain conditions, or net share settlement, if exercised. Accordingly, the August 2024 Common Stock Warrants were recorded at their grant date fair value with no subsequent remeasurement.
The Company evaluated the August 2024 Underwriter Warrants in accordance with the guidance at ASC 718, Compensation-Stock Compensation, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The August 2024 Underwriter Warrants are indexed to the common stock and are required to be settled through physical settlement, subject to certain conditions, or net share settlement, if exercised. Accordingly, the August 2024 Underwriter Warrants were recorded at their grant date fair value with no subsequent remeasurement. Further, the Company recognized the August 2024 Underwriter Warrants as a stock issuance costs as they are issued for services in connection with an offering, and therefore will account for these as a reduction of the proceeds in the August 2024 Offering.
The fair value of the August 2024 Common Stock Warrants, August 2024 Pre-funded Warrants, and August 2024 Underwriter Warrants were determined utilizing a Black-Scholes-Merton model, considering all relevant assumptions current at the date of issuance. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for further detail regarding how assumptions were determined. The grant date relative fair value of the August 2024 Common Stock Warrants, August 2024 Pre-funded Warrants and August 2024 Underwriter Warrants was estimated to be approximately $1.2 million, $0.5 million, and $0.2 million, respectively, and were recognized as additional paid-in capital in the consolidated balance sheet as the August 2024 Common Stock Warrants, August 2024 Pre-funded Warrants, and August 2024 Underwriter Warrants were determined to be equity classified, with the corresponding debit as an issuance cost of the related equity offering.
The following assumptions and key inputs were used to value the August 2024 Common Stock Warrants, August 2024 Pre-funded Warrants, and August 2024 Underwriter Warrants at the date of issuance:
August 2024 Common
Stock Warrants
August 2024 Pre-
Funded Warrants
August 2024
Underwriter Warrants
Risk-free interest rate
3.7
%
3.7
%
3.7
%
Expected term (years)
5
5
5
Expected volatility
111.00
%
111.00
%
111.00
%
Stock price on valuation date
$
18.00
$
18.00
$
18.00
Exercise price
$
15.93
$
0.002
$
26.25
Expected dividend
—
%
—
%
—
%
Accounting for Warrant Modification
In connection with the August 2024 Offering, on August 20, 2024, the Company entered into a warrant amendment agreement (the “August 2024 Warrant Amendment Agreement”) with the purchaser of the August 2024 Pre-Funded Warrants, pursuant to which the Company agreed to amend the purchaser’s (i) warrants to purchase up to 126,829 shares of common stock at an exercise price of $100 per share issued in November 2023 and (ii) warrants to purchase up to 109,999 shares of common stock at an exercise price of $82.50 per share issued in June 2021 (together, the “August 2024 Existing Warrants”), in consideration for such investor’s participation in the August 2024 Underwritten Offering and the payment of $2.50 per August 2024 Existing Warrant (which amount is included in the $21 offering price above) to (i) lower the exercise price of the August 2024 Existing Warrants to $15.93 per share and (ii) amend the expiration date of the August 2024 Existing Warrants to five years following the closing of the August 2024 Offering, effective upon the closing of the August 2024 Offering on August 22, 2024.
F-18
ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging ("ASC 815") require issuers to account for modifications or exchanges of freestanding equity-classified written call options (e.g., warrants) that remain equity classified after the modification or exchange based on the economic substance of the modification or exchange. Pursuant to ASC 480 and ASC 815, the Company accounts for modifications of equity-classified warrant agreements by recording any increase in fair value of the modified equity-classified warrant as an equity issuance cost that reduces additional paid-in capital. The increase in the fair value of the modified August 2024 Existing Warrants was determined to be $0.8 million.
The following assumptions and key inputs were used to value the modification of the warrants immediately before and immediately after the modification. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for details related to the determination of fair value for warrants:
Immediately before the modification
Immediately after the modification
June 2021
Common Stock
Warrants
November 2023
Common Stock
Warrants
June 2021
Common Stock
Warrants
November 2023
Common Stock
Warrants
Risk-free interest rate
4.10
%
3.70
%
3.70
%
3.70
%
Expected term (years)
1.76
4.25
5.00
5.00
Expected volatility
100.00
%
111.00
%
111.00
%
111.00
%
Stock price on valuation date
$
22.80
$
22.80
$
22.80
$
22.80
Exercise price
$
82.50
$
100.00
$
15.93
$
15.93
Expected dividend
—
%
—
%
—
%
—
%
December 2024 Underwritten Offering
On December 18, 2024, the Company completed an underwritten offering and the Company sold and issued (i) an aggregate of 600,000 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), (ii) Series A warrants exercisable for an aggregate of up to 300,000 shares of Common Stock (the “Series A Common Stock Warrants”) and (iii) Series B warrants exercisable for an aggregate of up to 600,000 shares of Common Stock (the “Series B Common Stock Warrants” and together with the Series A Common Stock Warrants, the “December 2024 Common Stock Warrants”), for aggregate net proceeds of $16.5 million (the “December 2024 Underwritten Offering”) after deducting placement offering costs, agent fees and expenses and other offering expenses payable by the Company of $1.5 million.
Each share of Common Stock was sold together with (i) a Series A Common Stock Warrant to purchase 0.5 of a share of Common Stock and (ii) a Series B Common Stock Warrant to purchase one share of Common Stock, at a combined public offering price of $30 per share of Common Stock and accompanying December 2024 Common Stock Warrants. The Series A Common Stock Warrants are exercisable immediately, expire six months from the date of issuance on June 18, 2025, and have an exercise price of $30 per whole share. The Series B Common Stock Warrants are exercisable immediately, expire 5 years from the date of issuance on December 18, 2029, and have an exercise price of $30 per share. The net proceeds to the Company from the December 2024 Underwritten Offering were approximately $16.5 million, after deducting placement offering costs, agent fees and expenses and other offering expenses payable by the Company.
The Company evaluated the December 2024 Common Stock Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The warrants are indexed to the Company’s common stock and are required to be settled through physical settlement or net share settlement, if exercised. Accordingly, the warrants were recorded at their grant date fair value with no subsequent remeasurement.
F-19
The fair value of the December 2024 Common Stock Warrants was determined utilizing a Black-Scholes-Merton model considering all relevant assumptions current at the date of issuance. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for further detail regarding how assumptions were determined. The grant date relative fair value of the Series A and Series B Common Stock Warrants was estimated to be $1.3 million and $6.8 million, respectively and such warrants were recognized as additional paid-in capital in the consolidated balance sheet as they were determined to be equity classified.
The following assumptions and key inputs were used to value the December 2024 Common Warrants at the date of issuance:
Series A Common
Stock Warrants
Series B Common
Stock Warrants
Risk-free interest rate
4.3
%
4.4
%
Expected term (years)
0.50
5.00
Expected volatility
120.00
%
111.00
%
Stock price on valuation date
$
28.80
$
28.80
Exercise price
$
30.00
$
30.00
Expected dividend
—
%
—
%
June 2025 Public Offering
On June 26, 2025, the Company entered into a placement agency agreement (the “June 2025 Placement Agency Agreement”) with A.G.P./Alliance Global Partners, as the placement agent (the “Placement Agent”), pursuant to which the Company sold in a public offering (i) an aggregate of 1,000,000 shares of the Company’s common stock, (ii) Series C warrants exercisable for an aggregate of up to 1,000,000 shares of common stock (the “Series C Common Warrants”) and (iii) Series D warrants exercisable for an aggregate of up to 1,000,000 shares of common stock (the “Series D Common Warrants” and together with the Series C Common Warrants, the “June 2025 Warrants”), for aggregate gross proceeds of $10.0 million (the “June 2025 Public Offering”). Each share of common stock was sold together with (i) a Series C Common Warrant to purchase one share of common stock and (ii) a Series D Common Warrant to purchase one share of common stock, at a combined public offering price of $10 per share of common stock and accompanying June 2025 Warrants. The Series C Common Warrants are exercisable immediately upon issuance, have a term of five years from the date of issuance and have an exercise price of $10 per share. The Series D Common Warrants are exercisable immediately upon issuance, have a term of twelve months from the date of issuance and have an exercise price of $10 per share. The net proceeds to the Company from the June 2025 Public Offering were approximately $9.0 million, after deducting placement agent fees and expenses and other offering expenses payable by the Company.
The Company evaluated the June 2025 Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The June 2025 Warrants are indexed to the Company’s common stock and are required to be settled through physical settlement or net share settlement, if exercised. Accordingly, the June 2025 Warrants were recorded at their grant date fair value with no subsequent remeasurement.
The fair value of the June 2025 Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for further detail regarding how these assumptions were determined. The grant date relative fair value of the Series C and Series D Common Warrants was estimated to be $3.1 million and $2.0 million, respectively, recognized as additional paid-in capital in the consolidated balance sheet as they were determined to be equity classified and categorized as Level 3 within the fair value hierarchy.
F-20
The following assumptions and key inputs were used to value the June 2025 Warrants at the date of issuance:
Series C Common
Stock Warrants
Series D Common
Stock Warrants
Risk-free interest rate
3.8
%
4.0
%
Expected term (years)
5.00
1.00
Expected volatility
119.00
%
157.00
%
Stock price on valuation date
$
7.20
$
7.20
Exercise price
$
10.00
$
10.00
Expected dividend
—
%
—
%
September 2025 Public Offering
On September 18, 2025, the Company entered into a placement agency agreement (the “September 2025 Placement Agency Agreement”) with the Placement Agent, pursuant to which the Company sold in a public offering (i) an aggregate of 1,350,000 shares of the Company’s common stock, (ii) Series E warrants exercisable for an aggregate of up to 1,350,000 shares of common stock (the “Series E Common Warrants”) and (iii) Series F warrants exercisable for an aggregate of up to 1,350,000 shares of common stock (the “Series F Common Warrants” and together with the Series E Common Warrants, the “September 2025 Warrants”), for aggregate gross proceeds of $9.0 million (the “September 2025 Public Offering”). Each share of common stock was sold together with (i) a Series E Common Warrant to purchase one share of common stock and (ii) a Series F Common Warrant to purchase one share of common stock, at a combined public offering price of $134 per share of common stock and accompanying September 2025 Warrants. The Series F Common Warrants are exercisable immediately upon issuance, have a term of five years from the date of issuance and have an exercise price of $134 per share. The Series E Common Warrants are exercisable immediately upon issuance, have a term of twelve months from the date of issuance and have an exercise price of $134 per share. The net proceeds to the Company from the September 2025 Public Offering were approximately $8.1 million, after deducting placement agent fees and expenses and other offering expenses payable by the Company.
The Company evaluated the September 2025 Warrants in accordance with the guidance at ASC 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging, and determined that they should be classified as equity instruments, with no recurring fair value measurement required. The September 2025 Warrants are indexed to the Company’s common stock and are required to be settled through physical settlement or net share settlement, if exercised. Accordingly, the September 2025 Warrants were recorded at their grant date fair value with no subsequent remeasurement.
The fair value of the September 2025 Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance. Refer to Note 2, Summary of Significant Accounting Policies and Basis of Presentation, for further detail regarding how these assumptions were determined. The grant date relative fair value of the Series E Common Warrants and Series F Common Warrants was estimated to be $2.9 million and $1.8 million, respectively, recognized as additional paid-in capital in the consolidated balance sheet as they were determined to be equity classified and categorized as Level 3 within the fair value hierarchy.
The following assumptions and key inputs were used to value the September 2025 Warrants at the date of issuance:
Series E Common
Stock Warrants
Series F Common
Stock Warrants
Risk-free interest rate
3.7
%
3.6
%
Expected term (years)
5.00
1.00
Expected volatility
129.00
%
154.00
%
Stock price on valuation date
$
6.20
$
6.20
Exercise price
$
6.70
$
6.70
Expected dividend
—
%
—
%
F-21
5. STOCKHOLDERS' EQUITY, EQUITY INCENTIVE PLANS, AND STOCK-BASED COMPENSATION
Our authorized capital stock consists of:
•
515,000,000 shares of common stock, par value $0.0001 per share; and
•
10,000,000 shares of preferred stock, par value $0.0001 per share.
On December 18, 2025, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the Company’s authorized shares of common stock, par value $0.0001 per share, from 315,000,000 to 515,000,000.
As of December 31, 2025 there were 5,872,865 shares of our common stock outstanding, and no shares of preferred stock outstanding. As of December 31, 2024, there were 2,359,327 shares of our common stock outstanding, and no shares of preferred stock outstanding.
Common Stock
Voting. The holders of our common stock are entitled to one vote for each share held of record on all matters on which the holders are entitled to vote (or consent pursuant to written consent). Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote.
Dividends. The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.
Liquidation Rights. In the event of the Company’s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock.
Conversion Right. The holders of common stock have no conversion rights.
Preemptive and Similar Rights. The holders of common stock have no preemptive or similar rights.
Redemption/Put Rights. There are no redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock will be fully-paid and nonassessable.
Preferred Stock
Our board of directors has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted.
Equity Offering Activity
On May 29, 2024, the Company closed the sale of 94,937 shares of common stock and the May 2024 Warrants, pursuant to the securities purchase agreement entered into between the Company and several purchasers on May 28, 2024. Refer to Note 4, Warrants, for additional details.
On August 22, 2024, we completed an underwritten offering for the issuance and sale of 163,813 shares of common stock, the August 2024 Warrants and the August 2024 Pre-funded Warrants. Refer to Note 4, Warrants, for additional details.
F-22
On December 18, 2024 the Company closed the sale of the December Underwriting Agreement for the offering, issuance and sale of 600,000 shares of common stock and December 2024 Common Stock Warrants. Refer to Note 4, Warrants, for additional details.
On June 26, 2025, the Company closed the sale of 1,000,000 shares of common stock, the Series C Common Warrants, and the Series D Common Warrants as part of a public offering. Refer to Note 4, Warrants, for additional details.
On September 18, 2025, the Company closed the sale of 1,350,000 shares of common stock, the Series E Common Warrants, and the Series F Common Warrants as part of a public offering. Refer to Note 4, Warrants, for additional details.
As of December 31, 2025, the Company has shares of common stock reserved for future issuance as follows:
Shares underlying outstanding warrants
5,442,508
Shares reserved for future grants under the 2020 Equity Incentive Plan
340,793
Shares underlying outstanding stock options
158,098
Total common stock reserved for future issuance
5,941,399
May 2025 ATM Sales Agreement
On May 30, 2025, the Company entered into an at market issuance sales agreement (the “May 2025 ATM Sales Agreement”) with B. Riley Securities, Inc. and Alliance Global Partners serving as agents (the “Agents”), with respect to an at-the-market ("ATM") offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $50 million through the Agents. During the year ended December 31, 2025, the Company sold 150,800 shares of common stock pursuant to the May 2025 ATM Sales Agreement for net proceeds of approximately $1.5 million after deducting sales agent commissions and other offering expenses of approximately $0.4 million.
2020 Equity Incentive Plan
During the year ended December 31, 2025, in accordance with the “evergreen” provision in the Company's 2020 Equity Incentive Plan (the "Evergreen Provision"), an additional 232,896 shares (the “Evergreen Shares”) were automatically made available for issuance for future awards under such plan on the first day of 2025, which represents 10% of the number of shares of common stock outstanding on December 31, 2024. The Evergreen Shares are included in the 2020 Equity Incentive Plan share reserve as of December 31, 2025. As of December 31, 2025, the Company had 340,793 shares reserved for future grants under the 2020 Equity Incentive Plan. Following the December 31, 2025 balance sheet date, in accordance with the Evergreen Provision, an additional 584,250 shares were automatically made available for issuance under the plan on the first day of 2026, representing approximately 10% of the number of shares of common stock outstanding on December 31, 2025.
In August 2025, the Company awarded 15,000 shares of restricted common stock to a consultant in exchange for services to be provided, all of which were vested as of December 31, 2025. These shares of restricted common stock were issued pursuant to the Company's 2020 Equity Incentive Plan. The fair value of these shares of restricted common stock was determined based on the share price of the Company as of the grant date, and was approximately $0.2 million.
Stock-based Compensation Expense
The Company records stock-based compensation expense based on the fair value of stock options and shares of restricted common stock granted to employees, non-employee consultants and non-employee directors. During the years ended December 31, 2025 and 2024, the Company recorded stock-based compensation expense of approximately $2.2 million and $1.6 million, respectively. As of December 31, 2025, the Company had unrecognized stock-based compensation expense of $1.2 million, which is expected to be recognized over a weighted-average period of 1.4 years.
F-23
The fair value of options granted during the year ended December 31, 2025 and 2024 used the following ranges of assumptions and key inputs:
Black-Scholes-Merton Inputs
Year Ended
December 31, 2025
Year Ended
December 31, 2024
Risk-free interest rate
3.7%
-
4.4
%
3.4%
-
4.2
%
Expected term (in years)
5.4
-
6.1
5.0
-
5.6
Expected volatility
110%
-
130
111%
-
118
%
Expected dividend yield
—
%
—
%
The weighted average fair value of stock options granted for the year ended December 31, 2025 and 2024 was $28.40 and $20.20, respectively. The options have a contractual term of 10 years.
Activity under the Company's equity compensation plan for the years ended December 31, 2025 and 2024 is as follows:
Number of
Options
Outstanding
Weighted
Average
Exercise
price per
share
Weighted
Average
Remaining
Contractual
Term in Years
Aggregate
Intrinsic
Value
Balance, December 31, 2023
79,028
$
130.20
9.11
$
300,969
Granted*
54,780
24.20
—
—
Expired/Cancelled
(5,837
)
205.40
—
—
Balance, December 31, 2024
127,971
$
81.40
8.88
$
683,016
Granted
47,627
34.60
Expired/Cancelled
(17,500
)
67.80
—
—
Balance, December 31, 2025
158,098
$
68.80
8.22
$
—
Options vested and exercisable at December 31, 2025
121,693
$
76.80
8.05
$
—
* For the year ended December 31, 2024, the Company settled certain accrued bonus amounts through the issuance of a total of 16,641 stock options to certain employees, in lieu of cash bonuses. The fair value of those stock options was approximately $330,816 and this amount was recorded directly to additional paid-in capital on the consolidated balance sheet as the stock options were issued to settle an accrued bonus amount for which the associated expense was previously recognized in the consolidated statement of operations. This amount is not included within the expenses disclosed below.
For the year ended December 31, 2025 and 2024, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows:
Year Ended December 31,
2025
2024
Research and development
$
839,015
$
950,247
General and administrative
1,388,844
680,094
Total stock-based compensation expense
$
2,227,859
$
1,630,341
F-24
6. COMMITMENTS AND CONTINGENCIES
Clinical trials
Since 2010, the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company’s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it may suffer as a result of third-party claims; the Company maintains product liability insurance in conjunction with this indemnification. The agreements may be terminated upon 30 days’ written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records.
Indemnification
From time to time, in its normal course of business, the Company may indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or third-party infringement claims. It may not be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been no such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer.
Operating Leases
The Company leases a corporate office located at 10080 N. Wolfe Road, Suite SW3-200, Cupertino, CA 95014. The lease has a 12-month term and includes a renewal option. The operating lease cost for the years ended December 31, 2025 and 2024 was approximately $55,400 and 50,180, respectively. The lease was renewed in January 2026 for an additional twelve months, with a monthly lease payment of approximately $4,800.
Litigation
The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
7. FAIR VALUE MEASUREMENTS
The following tables provide a summary of the assets and liabilities that are required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of December 31, 2025 and 2024:
December 31, 2025
Level 1
Level 2
Level 3
Total
Assets:
Money market funds (cash equivalents)
$
13,228,720
$
—
$
—
$
13,228,720
Total assets measured and recorded at fair value
$
13,228,720
$
—
$
—
$
13,228,720
F-25
December 31, 2024
Level 1
Level 2
Level 3
Total
Assets:
Money market funds (cash equivalents)
$
12,203,627
$
—
$
—
$
12,203,627
Total assets measured and recorded at fair value
$
12,203,627
$
—
$
—
$
12,203,627
Liabilities:
Warrant liabilities
$
—
$
—
$
89,010
$
89,010
Total liabilities measured and recorded at fair value
$
—
$
—
$
89,010
$
89,010
The following table summarizes the changes in the fair value of the warrant liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
Year Ended December 31,
2025
2024
Balance, beginning of period
$
89,010
$
806,655
Change in fair value of warrant liabilities
(89,010
)
(717,645
)
Balance, end of period
$
—
$
89,010
In prior years, the Company issued warrants to purchase 27,816 shares of common stock in a private-placement (the "Private Warrants") and classified the warrants as derivative liabilities, pursuant to ASC 815, as the Private Warrants have an exercise price that is subject to potential adjustment, with subsequent changes in their fair values to be recognized in the consolidated statement of operations at each reporting date. The Company calculated the fair value of the Private Warrants as of December 31, 2024 as $89,010 using a Lattice model. The Private Warrants expired on December 14, 2025. Upon expiration, the associated warrant liabilities were derecognized, and the remaining fair value was written off through the consolidated statement of operations.
The assumptions and key inputs used in the Lattice calculation were the following:
December 31, 2024
Risk-free interest rate
4.17
%
Remaining expected term of Private Warrants
0.95
Expected volatility(1)
128.70
%
Stock price on valuation date
$
36.20
Exercise price
$
230.00
Expected dividend
—
%
(1) Based on volatility implied by the Company's publicly traded warrant market price.
F-26
8. INCOME TAXES
As a result of the Company's history of net operating losses and the full valuation allowance against its deferred tax assets, there was no current or deferred income tax provision other than current state minimum taxes and current foreign taxes for the years ended December 31, 2025 and 2024.
Domestic and international pre-tax income/(loss) consists of the following:
December 31,
2025
2024
United States
$
(19,934,208
)
$
(29,847,961
)
International
88,195
(51,327
)
Loss before income taxes
$
(19,846,013
)
$
(29,899,288
)
The provision for income taxes is attributable to operations and is comprised of the following:
December 31,
2025
2024
Current:
Federal
$
—
$
—
State
9,036
2,100
Foreign
9,853
17,414
Current total
$
18,889
$
19,514
Deferred:
Federal
$
—
$
—
State
—
—
Foreign
—
—
Deferred total
—
—
Provision for income taxes
$
18,889
$
19,514
The Company has elected to prospectively adopt the guidance in ASU No, 2023-09, 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The reconciliation of the federal statutory income tax rate to the Company's provision for income taxes for the year ended December 31, 2025 in accordance with the guidance in ASU No. 2023-09 is as follows:
December 31, 2025
Amount
Percentage
U.S. Federal statutory tax rate
$
(4,167,663
)
21.0
%
State and local income taxes, net of federal income tax effect
1,659
—
%
Foreign tax effects - India
(5,183
)
—
%
Changes in valuation allowances
3,837,241
(19.3
) %
Nontaxable or nondeductible items
349,384
(1.8
) %
Other
3,451
—
%
Provision for income taxes
$
18,889
(0.1
)%
Reconciliation to the statutory federal income tax rate and the Company's effective tax rate for the year ended December 31, 2024, consist of the following:
2024
U.S. Federal statutory tax rate
$
(6,278,850
)
State and local income taxes, net of federal income tax effect
127,499
Warrant expense
(150,705
)
Stock-based compensation
56,333
Foreign rate differential
(2,053
)
State true up
2,242,134
Other permanent differences
41,024
Valuation allowance
3,994,770
Other
(10,638
)
Provision for income taxes
$
19,514
F-27
The components of deferred tax assets included on the balance sheet are:
December 31,
2025
2024
NOL carryforwards
$
18,966,713
$
15,687,479
Accruals and reserves
8,402
(28,852
)
Stock-based compensation
1,356,257
1,135,026
Capitalized Section 174
14,975,473
14,681,051
Others
18,736
13,636
35,325,581
31,488,340
Valuation allowance
(35,325,581
)
(31,488,340
)
Net deferred tax assets
—
—
Deferred income taxes
$
—
$
—
Management has determined based on all the available information that a 100% valuation reserve is required against its deferred tax assets due to the uncertainty surrounding realization of such assets. Total increase in the valuation allowance is $3.8 million and $4.0 million for the years ending December 31, 2025 and 2024, respectively.
As of December 31, 2025, the Company currently has net operating loss carryforwards of approximately $87.4 million and $8.7 million for U.S. Federal and state purposes, respectively. Approximately $35.9 million of the U.S. Federal losses begin to expire in 2029. The balance, all post-2017 federal net operating losses may be carried forward indefinitely.
As of December 31, 2025, the Company had $1.9 million research and development credit carryforwards to offset federal income taxes and $0.3 million of California research credit carryforwards to offset state income taxes. Both the federal and California credits will begin to expire in 2042 if unutilized.
Under the provisions of the Internal Revenue Code, the NOL's and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. Utilization of the net operating loss and tax credits carryforwards may be limited by “ownership change” rules, as defined in Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization.
The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense. As of December 31, 2025, the Company has no accrual for payment of interest related to unrecognized tax benefits.
The Company’s income tax returns for all years remain open to examination by federal and state taxing authorities. The Company does not expect that is unrecognized tax benefit will change significantly in the next 12 months.
As of December 31, 2025 the Company has $2.1 million unrecognized tax benefits that, if recognized, would change its effective rate. The Company’s unrecognized tax benefit relates entirely to the federal and California research credits. The total increase in the unrecognized tax benefits is $0.4 million and $0.9 million for the years ending December 31, 2025 and 2024, respectively.
December 31, 2025
December 31, 2024
Balance, beginning of period
$
1,704,925
$
802,571
Prior Year Increase/ (Decrease)
—
134,291
Current Year Increase/ (Decrease)
431,969
768,063
Balance, end of period
$
2,136,894
$
1,704,925
F-28
9. SEGMENT INFORMATION
The Company views its operations and manages its business as one operating and reportable segment focused on developing new therapies that seek to address unmet medical needs in the areas of central nervous system ("CNS"), inflammatory and cardiometabolic diseases. The CODM, the Company's Chief Executive Officer, manages and allocates resources to the operations of the Company on a consolidated basis, considering primarily research and development expenditures and net loss. This enables the Chief Executive Officer to assess the Company's overall level of available resources and determine how best to deploy these resources in line with long-term company-wide strategic goals.
Consistent with the Company's management reporting, results of operations are reported on a consolidated basis for purposes of segment reporting. Net loss and research and development expenses are used to allocate resources and are reported on the consolidated statements of operations. The measure of segment assets is reported on the consolidated balance sheets as cash and cash equivalents.
The CODM does not review any measure of significant segment expenses or segment loss which differ from the level of reporting as reflected on the consolidated statement of operations.
10. SUBSEQUENT EVENTS
Reverse Stock Split
At Reviva's annual stockholders meeting held on December 18, 2025, the Company’s stockholders adopted and approved an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to December 31, 2026, with such ratio to be determined by our Board in its discretion.
On March 4, 2026, the Company filed the amendment to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's common stock at a ratio of one-for-twenty (1:20) (the “Reverse Stock Split”). The Reverse Stock Split became effective in accordance with the terms of the amendment at 12:01 a.m. Eastern Time on March 9, 2026 under a new CUSIP number, 76152G-209. All share, common stock warrant, prefunded warrant, restricted stock and common stock option amounts, and per share, per common stock warrant, per prefunded warrant, per restricted stock and per common stock option amounts, in this Annual Report on Form 10-K, have been retrospectively adjusted as appropriate to reflect the Reverse Stock Split.
ATM Sales Activity
From January 1, 2026 through February 26, 2026, the Company sold 570,845 shares of common stock pursuant to the May 2025 ATM Sales Agreement for net proceeds of approximately $2.5 million after deducting sales agent commissions and other offering expenses of approximately $0.1 million.
March 2026 Public Offering
On March 20, 2026, the Company closed a public offering (the “March 2026 Public Offering”) conducted pursuant to a placement agency agreement (the “March 2026 Placement Agency Agreement”) and securities purchase agreements with certain investors participating in the offering (the “March 2026 Securities Purchase Agreements”), pursuant to which the Company issued and sold (i) an aggregate of 6,283,334 shares of common stock, (ii) pre-funded warrants (the “March 2026 Pre-Funded Warrants”) exercisable for an aggregate of up to 383,333 shares of common stock (the “March 2026 Pre-Funded Warrant Shares”), (iii) Series G warrants (the “Series G Warrants”) exercisable for an aggregate of up to 6,666,667 shares of common stock (the “Series G Warrant Shares”) and (iv) Series H warrants (the “Series H Warrants” and together with the Series G Warrants, the “March 2026 Common Stock Warrants”) exercisable for an aggregate of up to 6,666,667 shares of common stock (the “Series H Warrant Shares” and together with the March 2026 Pre-Funded Warrant Shares and Series G Warrant Shares, the “March 2026 Warrant Shares”), for aggregate gross proceeds of $10.0 million. Each share of common stock (or March 2026 Pre-Funded Warrant in lieu thereof) was sold together with (i) a Series G Warrant to purchase one share of common stock and (ii) a Series H Warrant to purchase one share of common stock, at a combined public offering price of $1.50 per share of common stock and accompanying March 2026 Common Stock Warrants (or a combined public offering price of $1.4999 per March 2026 Pre-Funded Warrant and accompanying March 2026 Common Stock Warrants). The March 2026 Pre-Funded Warrants have an exercise price of $0.0001 per share and will expire when exercised in full. The Series G Warrants are exercisable immediately, have a term of five years from the date of issuance and have an exercise price of $1.50 per share. The Series H Warrants are exercisable immediately, have a term of twelve months and have an exercise price of $1.50 per share. The net proceeds to the Company from the March 2026 Public Offering were approximately $8.9 million, after deducting Placement Agent fees and expenses and other offering expenses payable by the Company.
F-29